During the hearing, an official from Novo Nordisk will be questioned about the pricing they charge for Ozempic and ...

After inking a related patent settlement last year, Viatris has cleared another obstacle in its quest to launch generic ...

The Delaware court ruled that Viatris’ drug does not infringe the "administered without another therapeutic agent" limitation ...

A federal court ruled in Mylan's favor, finding no infringement of Novo's patent tied to Wegovy, rejecting direct, ...

Novo Nordisk sees 65% obesity drug sales growth, forecasts $8.14–$9.59B FY25 free cash flow. Click here to read an analysis ...

Novo Nordisk ( ($NVO) ) has risen by 10.44%. Read on to learn why. Novo Nordisk has seen a notable 10.44% increase in its stock price over the ...

Viatris Inc.'s proposed copy of Novo Nordisk A/S’ Wegovy doesn’t infringe a patent on using the once-weekly obesity drug ...

Novo Nordisk has today launched its weight-loss injection Wegovy in Britain, its second debut in Europe in just over a month as the drugmaker seeks to expand in the region even as it struggles to ...

The partnership helps Novo capture patients who have been using compounded versions of the medicine, while allowing ...

Drug maker Novo Nordisk has landed in hot water in the UK over its promotional practices. Now RTÉ Investigates examines the company's links to medical experts in Ireland.

Diabetes and obesity drug developer Novo Nordisk on Thursday significantly raised its full-year operating profit and sales expectations on the back of strong demand for its highly popular Wegovy ...

COPENHAGEN (dpa-AFX) - Novo Nordisk (NVO) is broadening patient access to its FDA-approved weight management drug, Wegovy (semaglutide) 2.4 mg, through a new partnership with WeightWatchers starting ...